News on research and diagnostics for metabolic disorders and metabolic diseases.
CE marking of PromarkerD Hub complements the CE mark that the mass spectrometry version of the test received in November.
The Finnish biotechnology firm also announced plans to raise up to €80 million in the coming year.
The firm is conducting clinical trials in preparation for applying for FDA clearance to market its POC instrument and first assay in the first quarter of next year.
The firm said it anticipates launching the platform in Europe next year and completing its first round of external financing in the first quarter of 2020.
The FDA cleared the system, comprising a blood collection device and associated test to measure long-term glucose levels in patients with diabetes.
